BL9B Stock Chart & Stats
€148.00
€0.00(0.00%)
At close: 4:00 PM EDT
€148.00
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€124.90 - €157.50
Previous CloseN/A
Volume0.00
Average Volume (3M)4.00
Market Cap
€4.74B
Enterprise Value€5.36B
Total Cash (Recent Filing)€66.26M
Total Debt (Recent Filing)€142.44M
Price to Earnings (P/E)31.1
Beta0.33
Next Earnings
Feb 19, 2027EPS Estimate
1.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)5.34
Shares Outstanding31,777,325
10 Day Avg. Volume1
30 Day Avg. Volume4
Financial Highlights & Ratios
PEG Ratio1.53
Price to Book (P/B)3.98
Price to Sales (P/S)4.82
P/FCF Ratio28.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€187.13Price Target Upside26.44% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)4.88
Revenue Forecast (FY)€1.01B
Bulls Say, Bears Say
Bulls Say
Strong Profitability And Margin ExpansionImproving gross, operating, and net margins indicate stronger operating efficiency and a favorable earnings profile. If maintained, this profitability gives Balchem more capacity to fund product development, absorb cost pressure, and convert segment growth into durable earnings over the next several quarters.
Conservative Leverage And Financial FlexibilityVery low leverage reduces interest burden and financial risk while preserving borrowing capacity for innovation, capacity expansion, and acquisitions. The strong equity base also gives Balchem flexibility to sustain investment and manage operating volatility without relying heavily on external financing.
Broad-based Segment Growth And Differentiated OfferingsGrowth across all three reporting segments reduces reliance on a single end market and supports a more resilient business model. Specialty nutrients, delivery systems, and market penetration can deepen customer adoption and reinforce Balchem's position in quality-sensitive nutrition and specialty product applications.
Bears Say
Modest Recent Revenue GrowthThe recent top-line pace is modest relative to the company's stronger prior step-up, which may constrain operating leverage and limit the speed of earnings expansion. Sustained profitability therefore depends more heavily on mix, pricing, and execution until broader volume growth accelerates.
Input-cost Pressure Threatens MarginsPersistent raw-material inflation can pressure gross margins when customer price increases do not fully offset costs. Even with strong current profitability, recurring input-cost pressure could reduce earnings conversion and require ongoing pricing actions, efficiency gains, or favorable mix to protect returns.
Ongoing European Antidumping CircumventionContinued duty circumvention can weaken pricing discipline and delay volume recovery in European monogastrics, limiting the benefit of trade protections. Resolving the issue may require sustained enforcement and commercial effort, while pricing competition could weigh on segment profitability over the medium term.
Balchem News
BL9B FAQ
What was Balchem Corp.’s price range in the past 12 months?
Balchem Corp. lowest stock price was €124.90 and its highest was €157.50 in the past 12 months.
What is Balchem Corp.’s market cap?
Balchem Corp.’s market cap is €4.74B.
When is Balchem Corp.’s upcoming earnings report date?
Balchem Corp.’s upcoming earnings report date is Feb 19, 2027 which is in 113 days.
How were Balchem Corp.’s earnings last quarter?
Balchem Corp. released its earnings results on Oct 23, 2026. The company reported €1.309 earnings per share for the quarter, beating the consensus estimate of €1.282 by €0.027.
Is Balchem Corp. overvalued?
According to Wall Street analysts Balchem Corp.’s price is currently Undervalued.
Does Balchem Corp. pay dividends?
Balchem Corp. does not currently pay dividends.
What is Balchem Corp.’s EPS estimate?
Balchem Corp.’s EPS estimate is 1.26.
How many shares outstanding does Balchem Corp. have?
Balchem Corp. has 31,777,325 shares outstanding.
What happened to Balchem Corp.’s price movement after its last earnings report?
Balchem Corp. reported an EPS of €1.309 in its last earnings report, beating expectations of €1.282. Following the earnings report the stock price went up 2.387%.
Which hedge fund is a major shareholder of Balchem Corp.?
Currently, no hedge funds are holding shares in DE:BL9B
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Balchem Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€187.13 (26.44% Upside)
€187.13 (26.44% Upside)
Blogger Sentiment
Bullish
DE:BL9B Sentiment 100%
Sector Average 69%
Sector Average 69%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
7.84%
12-Months-Change
Fundamentals
Return on Equity
13.21%
Trailing 12-Months
Asset Growth
2.56%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Balchem Corp.
Balchem Corporation develops, manufactures, and distributes specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. The Human Nutrition & Health segment supplies ingredients in the food and beverage industry. Its products include spray dried and emulsified powders, extrusion and agglomeration, blended lipid systems, liquid flavor delivery systems, juice and dairy bases, chocolate systems, and cereal systems, as well as ice cream bases and variegates. This segment offers specialty vitamin K2; microencapsulation solutions for various applications; and human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. The Animal Nutrition & Health segment provides microencapsulated products to enhance health and milk production and delivering nutrient supplements in ruminant animals; chelation technology, which offers enhanced nutrient absorption for various species of production and companion animals; methylsulfonylmethane; and choline chloride, a nutrient for monogastric animal health. The Specialty Products segment distributes ethylene oxide and ammonia primarily for use in the health care industry; and single use canisters for sterilizing re-usable devices. This segment also markets and sells propylene oxide, a fumigant to aid in the control of insects and microbiological spoilage, as well as to reduce bacterial and mold contamination in shell and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs, and prunes; and chelated minerals for high value crops. It sells its products through sales force, independent distributors, and sales agents. The company was incorporated in 1967 and is headquartered in Montvale, New Jersey.
BL9B Company Deck
BL9B Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was strongly positive, with record consolidated financial results, growth across all three segments, expanding gross margins, strong cash generation, balance-sheet improvement, continued product and science investment, and confidence in ongoing year-over-year growth. The company also cited challenges including higher input costs, elevated inventory, trade-practice circumvention, oil-price pressure, and normal fourth-quarter seasonality, but these were outweighed by the reported achievements and outlook.View all DE:BL9B earnings summariesBL9B Stock 12 Month Forecast
Average Price Target
€187.13
▲(26.44% Upside)
Technical Analysis
Ashland
―
Innospec
―
International Flavors & Fragrances
―
Sensient Technologies
―
Stepan Company
―